One Day, Big Impact

The U.S. Food and Drug Administration has officially entered its “speed dating” era—at least when it comes to inspections. On May 6, 2026, FDA announced a pilot program for one-day inspectional assessments, a shorter, risk-based alternative designed to complement traditional, multi-day inspections.

While the concept sounds deceptively simple—“we’ll be in and out in a day”—the implications are anything but. This is not FDA doing less. It is FDA doing more, faster, and smarter.

The Concept: Inspection Lite (With a Catch)

At its core, the pilot allows FDA to conduct short, focused screening inspections targeting lower-risk facilities. These assessments are intended to:

• Expand FDA’s inspectional reach across more facilities
• Gather targeted compliance insights quickly
• Feed data into risk-based oversight models

Facilities are selected using risk-based factors such as product type, prior inspection history, and operational characteristics. And importantly, these one-day assessments are not a replacement for traditional inspections—they are an additional tool in FDA’s toolbox.

Translation: a one-day visit is not a “lighter” inspection—it is a screening mechanism that can escalate at any time.

The Strategic Shift: From Periodic to Persistent Oversight

The real story here is not the one-day format—it is what the format represents.

FDA is shifting toward a risk-tiered, data-driven inspection model, where:

• Lower-risk facilities receive shorter, more frequent touchpoints
• Higher-risk facilities receive deeper, resource-intensive scrutiny
• Inspection insights continuously feed back into FDA’s risk models

The pilot has already included dozens of facilities, with most resulting in No Action Indicated (NAI) outcomes—suggesting that FDA is using these visits to confirm compliance and refine its targeting approach.

In other words, this is surveillance, not leniency.

The Twist: Inspections That May (Quietly) Grow

Here is the part that should keep compliance teams awake:

FDA investigators retain full authority to expand the scope or duration of any one-day assessment if they observe potential issues.

So while the invitation may say “one day,” the reality is:

Every one-day assessment is a potential multi-day inspection in disguise.

And because these are framed as screening visits, firms may not get advance notice that the inspection is intended to be “short”—or that it is about to become very not short.

The AI Angle: The Invisible Hand Selecting You

Although FDA has not published detailed parameters, the agency has made clear that data and risk signals drive facility selection.

This includes:

• Prior compliance history
• Product risk
• Operational characteristics
• Trends identified from prior inspections

The takeaway is clear: your past compliance record is no longer just history—it is a predictive input.

You are not waiting for FDA to show up.

FDA’s models are deciding when and why they will.

How Industry Should Prepare (Hint: Assume You’re Up Next)

If the traditional inspection model allowed for long quiet periods between visits, this pilot disrupts that rhythm. The practical reality is that facilities must now operate as though they are in a state of continuous inspection readiness.

 

Align Registration With Reality

FDA is explicitly using discrepancies between registered and actual operations as a risk signal.

• Ensure listings, facility registrations, and product scope match real-world activities
• Verify contract manufacturing relationships are accurately reflected

Even small inconsistencies can turn a “one-day check” into a deeper inquiry.

 

Close the Loop on Prior Observations

A one-day assessment is perfectly suited for quick verification of corrective actions.

• Ensure CAPAs are not just documented—but demonstrably implemented
• Maintain evidence that fixes are durable, not cosmetic

If FDA can disprove your remediation in a few targeted questions, they will.

 

Be Audit-Ready at All Times

The “short notice” risk increases.

• Key records (batch records, SOPs, complaints, deviations) should be immediately retrievable
• Personnel should be trained to respond concisely and consistently

Think of this like a fire drill—but one where the fire marshal actually shows up.

 

Treat Every Interaction as High Stakes

Do not assume reduced scope equals reduced scrutiny.

• Inspectors can—and will—pivot if concerns arise
• Observations from one-day assessments can still result in Form FDA 483s

A fast inspection simply compresses risk into a shorter window.

Final Take: Faster Doesn’t Mean Easier

FDA’s one-day inspection pilot is a classic example of regulatory modernization:
more data, more coverage, less downtime—and sharper enforcement targeting.

For well-run, low-risk facilities, this may feel like a welcome efficiency gain. But for everyone else, it raises the stakes.

Because in FDA’s new world:

• Inspections may be shorter, but
• The time you have to demonstrate compliance just got shorter too.

And as always with FDA, the best strategy remains unchanged—

be inspection-ready before they knock…because now, they’re knocking more often.

 

For support on preparing for an FDA inspection including desktop or onsite audits, or for assistance with responses to Warning Letters, 483s or other inspection-related compliance or enforcement, please feel free to contact us at info@garg-law.com.